Alliance Global Partners initiated coverage on Sorrento Therapeutics
$SRNE
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Alliance Global Partners initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $35